OPNT - Opiant Pharmaceuticals, Inc.
| Previous Close | 14.28 |
| Open | 13.62 |
| Bid | 13.50 x 900 |
| Ask | 15.20 x 4000 |
| Day's Range | 13.62 - 15.68 |
| 52 Week Range | 9.98 - 18.23 |
| Volume | 34,442 |
| Avg. Volume | 19,441 |
| Market Cap | 62M |
| Beta (5Y Monthly) | 1.60 |
| PE Ratio (TTM) | 77.16 |
| EPS (TTM) | 0.20 |
| Earnings Date | Nov 12, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.00 |
- GlobeNewswire
Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of approximately $2.4 million from the total contract award of up to a maximum of approximately $4.6 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate Opiant’s development of OPNT003, nasal nalmefene, a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. Opiant intends to pursue a 505(b)(2) development path for OPNT003 and anticipates the potential to submit a New Drug Application for the drug and intranasal delivery device combination in the fourth quarter 2020.
- Simply Wall St.
A Closer Look At Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) Uninspiring ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Thomson Reuters StreetEvents
Edited Transcript of OPNT earnings conference call or presentation 12-Nov-19 9:30pm GMT
Q3 2019 Opiant Pharmaceuticals Inc Earnings Call
- Insider Monkey
Opiant Pharmaceuticals, Inc. (OPNT): Hedge Funds Watching From Afar
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Zacks Small Cap Research
OPNT: Research and Development Meeting Highlights Development Products…
By David Bautz, PhD NASDAQ:OPNT READ THE FULL OPNT RESEARCH REPORT Business Update R&D Meeting Highlights Pipeline of Addiction and Drug Overdose Treatments On October 17, 2019, Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) held a research and development meeting to highlight the companies most advanced programs for treating addiction and drug overdose. The slide presentation for the event can
- Benzinga
The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 12) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Allergan ...
- GlobeNewswire
Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Nov. 12, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
- GlobeNewswire
Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12
SANTA MONICA, Calif., Nov. 05, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
- Simply Wall St.
Can You Imagine How Chuffed Opiant Pharmaceuticals's (NASDAQ:OPNT) Shareholders Feel About Its 227% Share Price Gain?
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, if...
- GlobeNewswire
Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose
SANTA MONICA, Calif., Oct. 10, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and.
- GlobeNewswire
Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
SANTA MONICA, Calif., Sept. 24, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- GlobeNewswire
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced the appointments of Aziz Mottiwala as Opiant’s Chief Commercial Officer, and Rahsaan Thompson, Esq., as General Counsel, two newly created positions, effective September 16, 2019. Mr. Mottiwala will be responsible for building Opiant’s commercial organization and pre-commercial activities, as appropriate. Mr. Thompson will be responsible for all legal aspects of corporate strategy, intellectual property, transactions, compliance and regulatory matters. Both Mr. Mottiwala and Mr. Thompson will report directly to Roger Crystal, M.D., Chief Executive Officer of Opiant.
- Simply Wall St.
What You Must Know About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) Beta Value
Anyone researching Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) might want to consider the historical volatility of the...
- GlobeNewswire
Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
SANTA MONICA, Calif., Aug. 27, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- Thomson Reuters StreetEvents
Edited Transcript of OPNT earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Opiant Pharmaceuticals Inc Earnings Call
- Zacks Small Cap Research
OPNT: Increased Revenue Guidance for NARCAN® Nasal Spray…
The company recorded a total of $6.8 million in revenue for the three months ending June 30, 2019, which consisted of $6.1 million in royalty revenue from the sale of NARCAN® Nasal Spray, $0.1 million from grant and contract revenue, and $0.6 million from treatment investment revenue. The increase was attributable to an increase in sales of NARCAN® Nasal Spray by Emergent BioSolutions (EBS), which totaled $73 million in the second quarter of 2019.
- GlobeNewswire
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Aug. 08, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- GlobeNewswire
Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8
SANTA MONICA, Calif., July 30, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- Simply Wall St.
Should You Worry About Opiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) CEO Salary Level?
Roger Crystal became the CEO of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) in 2009. First, this article will compare...
- GlobeNewswire
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (SNY) to manufacture Opiant’s investigational agent OPNTOO4 (drinabant) for the treatment of Acute Cannabinoid Overdose (ACO). Opiant intends to reformulate drinabant, a high affinity, selective cannabinoid receptor antagonist, for parenteral administration in an emergency department setting. Opiant licensed exclusive global rights from Sanofi for the development and commercialization of drinabant for the emergency treatment of ACO.
- Simply Wall St.
Can We See Significant Insider Ownership On The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Share Register?
Every investor in Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) should be aware of the most powerful shareholder groups...
- Thomson Reuters StreetEvents
Edited Transcript of OPNT earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Opiant Pharmaceuticals Inc Earnings Call
- Zacks Small Cap Research
OPNT: Encouraging Pharmacokinetic Data for OPNT003…
The company recorded a total of $5.4 million in revenue for the three months ending Mar. 31, 2019, which consisted of $3.7 million in royalty revenue from the sale of NARCAN® Nasal Spray, $1.6 million of grant and contract revenue, and $0.08 million from treatment investment revenue. This compares to royalty revenue of $1.6 million for the three months ended Mar. 31, 2018. The increase in royalty revenue is due to the increase in sales of NARCAN® Nasal Spray by Emergent BioSolutions (EBS), which totaled $65.5 million in the first quarter of 2019.
- GlobeNewswire
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., May 09, 2019 -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
- GlobeNewswire
Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
SANTA MONICA, Calif., April 30, 2019 -- Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug.
